Yazar "Yavuz, Sinan" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Yayın
    Anti?HCV and HCV?RNA prevalence and clinical correlations in cases with non?Hodgkin's lymphoma
    (Wiley Online Library, 2003) Paydaş, Semra; Kılıç, Banu; Yavuz, Sinan; Disel, Umut; Tanrıverdi, Kahraman; Şahin, Berksoy; Burgut, Hüseyin Refik
    Hepatitis C virus (HCV) is an RNA virus in the Flaviviridae family. It displays lymphotropism in addition to hepatotropism and extrahepatic manifestations are very well known. There are many studies showing an association between HCV infection and non?Hodgkin's lymphomas (NHL). In this study the evidence for HCV infection was studied in cases with NHL. To this end, anti?HCV antibody and HCV?RNA were screened in serum samples of cases with NHL using third?generation ELISA and RT?PCR. Anti?HCV antibody was studied in 223 patients and was found to be positive in 18 cases (8.1%). Anti?HCV antibody positivity was compared with our blood bank / blood donor population. There was an important increased risk of HCV infection—the common odds ratio was 34.56 and corrected odds ratio was 19.07. HCV?RNA was studied in 67 of 223 serum samples. HCV?RNA was found to be positive in 21 of 67 samples (31.3%). When compared with clinico?demographic parameters for anti?HCV and HCV?RNA, including age, nodal status, and grade (in evaluable cases), except age in cases with or without HCV?RNA, we did not find an important correlation with HCV status and clinical findings (P = 0.155; 0.442; 0.288 for anti?HCV and 0.027; 0,558; 0.126, respectively). These results suggest that HCV infection may be an important risk factor for lymphomagenesis and HCV?RNA is more useful for the detection of HCV infection in these immunosuppressed cases. Simultaneous detection of anti?HCV and HCV?RNA will be more informative in this population.
  • Küçük Resim Yok
    Yayın
    Detection of hepatitis C virus RNA in paraffin-embedded tissues from patients with non-Hodgkin's lymphoma
    (National Center for Biotechnology Information, 2004) Paydaş, Semra; Ergin, Melek; Tanrıverdi, Kahraman; Yavuz, Sinan; Disel, Umut; Kılıç, Nil Banu; Erdoğan, Şeyda; Şahin, Berksoy; Tunçer, İlhan; Burgut, Hüseyin Refik
    The aim of this study is to detect the possible role of hepatitis C Virus (HCV) in lymphomagenesis. HCV-RNA and anti-HCV antibodies were studied in tissue and serum samples taken from patients with non-Hodgkin's Lymphoma (NHL). The prevalence of HCV, the clinical presentation of these cases, and association with histologic subtypes were determined. RT-PCR was used to detect the HCV-RNA in serum and tissue samples. The anti-HCV antibodies were tested with microparticle enzyme immunoassay. Immunohistochemistry with the ABC method was used to detect the HCV core protein in HCV-RNA(+) cases. RNA could be detected in 30 of 35 cases, and other tests were performed in these 30 samples. HCV-RNA was detected in 11 tissue samples (11/30, 37%). HCV core protein was studied in 10 of 11 HCV-RNA(+) cases, and 1-3% nuclear staining was found in only 2 samples. Serologically, HCV-RNA was detected in 7 of 30 samples (23.3%) and anti-HCV antibody was detected in 3 of 30 samples (10%). Detection of HCV-RNA in 37% of the lymphoma tissue samples suggests that HCV may have a role or is a contributing factor in the pathogenesis of lymphoma. The very low HCV core protein in lymphoma tissues may be due to the low viral load in lymphoid tissues and/or higher sensitivity of the PCR method. Detection of anti-HCV antibody in only three cases may be associated with undetectable levels of antibodies due to the immune deficiency in cases with NHL.
  • Küçük Resim Yok
    Yayın
    PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects
    (National Center for Biotechnology Information, 2005) Paydaş, Semra; Tanrıverdi, Kahraman; Yavuz, Sinan; Disel, Umut; Başlamışlı, Fikri; Burgut, Hüseyin Refik
    The PRAME (preferentially expressed antigen of melanoma) gene has been shown to be expressed in high levels in some solid tumors and hemopoietic neoplasias but not or only weakly expressed in normal tissues. It encodes an antigen recognized by autologous cytolytic T lymphocytes. PRAME is a good candidate for tumor immunotherapy and is a useful marker gene for detection of minimal residual disease (MRD). In this study, PRAME mRNA using real-time RT-PCR was studied in 74 adult cases with acute leukemia-68 had de-novo acute leukemia, 3 had chronic myeloid leukemia-blastic crisis (CML-BC), and 3 had myelodysplastic/myeloproliferative syndrome-blastic transformation (MDS/MPD-BT)-and the results were compared with 30 age-matched healthy volunteers. Nineteen of 74 cases with leukemia expressed PRAME, while only 2 controls showed weak expression. The prevalence of PRAME expression in AML and ALL cases was 30% and 17%, respectively. We did not find any important correlation between PRAME expression and clinical characteristics, such as age, sex, organomegaly/lymphadenopathy, Hb, WBC count, platelet count, LDH level, alkaline phosphatase, albumin, cell-surface antigens, response to therapy, or progression-free and overall survival. PRAME was monitored in 15 cases during remission and/or relapse. There was a good correlation between PRAME mRNA and hematological remission and/or relapse. Interestingly, PRAME was very high in one case with AML but was not found 3 months after allogeneic transplantation. PRAME mRNA is observed in about one-third of AML cases; it may be a useful marker to detect MRD, and it may also be a good predictor for the timing of donor lymphocyte infusions (DLI) in the post-transplant period in cases of molecular relapse.